Aptose Biosciences Inc.

APS.TOTSXHealthcare● Active

$2.20

+$0.00(+0.00%)

Market Cap$5615344

P/E Ratio—

52W High$2.59

52W Low$1.02

Avg Volume4K

Open$2.20

Beta0.30

Cash on Hand Financials Revenue

Aptose Biosciences Inc. (APS.TO) Cash on Hand — Cash & Short-Term Investments

Cash & cash equivalents plus short-term investments from the balance sheet, YoY change, and net cash vs debt context.

APS.TO · cash on hand · updated Dec 31, 2025

Core cash position

as of Dec 31, 2025

Cash & Short-Term Investments (CCE + ST Investments)

$4.1M▼ -33.5% vs prior year

FY · as of Dec 31, 2025 · Reported in USD

Cash & Cash Equiv. (CCE)

$4.1M

cashAndCashEquivalents

Short-Term Investments

shortTermInvestments

YoY Change vs Prior Year

-33.5%

vs prior fiscal year

Latest Quarter

$4.1M

Q1 2026

Data Scope & Methodology

Cash on Hand = Cash & Cash Equivalents (CCE) + Short-Term Investments, as reported on the balance sheet (10-K/10-Q). Also referred to as cash reserves or cash position. Not free cash flow.

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · Reported in USD

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · USDUpdated: December 31, 2025

Net cash vs debt

Cash vs Debt · Balance Sheet Health

Cash & ST Investments$4.1MCash on Hand

Total Debt$28.0MTotal Debt

Net Cash / Net Debt−$23.9MNet Debt Position

Cash vs Debt Ratio

Cash 13%Aptose Biosciences Inc. cash as % of market cap: 72.81%% · MCap $0BDebt 87%

Aptose Biosciences Inc. carries a net debt position of $23.9M. Total debt ($28.0M) exceeds cash on hand ($4.1M). Aptose Biosciences Inc. cash vs debt ratio: 13% cash / 87% debt.

Net Cash = Cash & ST Investments − Total Debt$4.1M − $28.0M = −$23.9M

Cash on hand history

annual cash on hand trend · Cash & Short-Term Investments

YoY Increase

YoY Decrease

Latest Year

APS.TO annual cash on hand history · Cash & Short-Term Investments · Source: FMP /balance-sheet-statement

Annual cash on hand by year

APS.TO cash & short-term investments history

DatePeriodCash & ST InvestmentsYoY Change

Dec 31, 2025LatestFY$4.1M-33.5%

Dec 31, 2024FY$6.2M-33.5%

Dec 31, 2023FY$9.3M-80.3%

Dec 31, 2022FY$47.0M-40.7%

Dec 31, 2021FY$79.1M-35.3%

APS.TO cash on hand annual historical data · Cash & Short-Term Investments per balance sheet (10-K/10-Q) · Reported in USD · Source: FMP /balance-sheet-statement

Healthcare Sector Cash Reserves Comparison

APS.TO vs peers · cash on hand

#CompanyCash & ST Inv.Market CapCash/MCapRelative

UnitedHealth Group Incorporated

Eli Lilly and Company

Aptose Biosciences Inc.YOU

APS.TO

$4.1M$6M72.8%

Healthcare sector cash reserves · Source: FMP /balance-sheet-statement + /profile · Sorted by Cash desccompanies with most cash on hand →

About cash on hand & methodology

Aptose Biosciences Inc. (APS.TO) cash on hand as of December 31, 2025 is $4.1M, comprising $4.1M in cash and cash equivalents (CCE) plus $0 in short-term investments — reported as Aptose Biosciences Inc. cash and short-term investments on the balance sheet (10-K filing). Also referred to as Aptose Biosciences Inc. cash reserves or cash position.

Aptose Biosciences Inc. annual cash on hand history shows decreased -33.5% in 2025: decreased -33.5% in 2025. Aptose Biosciences Inc. cash reserves in 2025 reflect the company's capital allocation strategy.

Aptose Biosciences Inc. carries total debt of $28.0M against cash of $4.1M, resulting in a net debt position of -$23.9M. For the full balance sheet, see the Financials → Balance Sheet tab.

Figures tie to SEC 10-K/10-Q balance sheet disclosures and FMP /balance-sheet-statement where noted.

Financial statements Free cash flow Net income Revenue Market cap P/E ratio Earnings Price history

Frequently asked questions

APS.TO cash on hand · 5 questions

As of December 31, 2025, Aptose Biosciences Inc. (APS.TO) has $4,088,545 in cash on hand — defined as cash and short-term investments on the balance sheet. This includes $4,088,545 in cash and cash equivalents (CCE) plus $0 in short-term investments. Latest quarter (March 31, 2026): $4,107,901. Data sourced from the annual 10-K filing via FMP.

APS.TO cash on handAPS.TO cash reservesAPS.TO cash 2025how much cash does APS.TO have

▸ Source: FMP /balance-sheet-statement · US GAAP · Aptose Biosciences Inc. · Aptose Biosciences Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: December 31, 2025